Full history for every metric is available with a Kvantra account
Mersana Therapeutics, Inc. (MRSN)
Key financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 42 | 1 | 0 | 27 | 37 | 40 | 33 |
| Operating profit | $m | -73 | -67 | |||||
| Net profit | $m | -28 | -88 | -170 | -204 | -172 | -69 | -70 |
| EPS reported | $ | -14.12 | -14.09 | |||||
| Operating cashflow per share | $ | -16.80 | -11.05 | |||||
| Capex per share | $ | 0.03 | 0.00 | |||||
| FCF per share | $ | -16.83 | -11.05 | |||||
| Free cash flow | $m | -82 | -74 | |||||
| Net debt | $m | -111 | -56 | |||||
| Book value equity | $m | -10 | - | |||||
| Book value per share | $ | -1.94 | - | |||||
| Number of shares | m | 4.9 | 4.99 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | -18.43 | -2.44 | |||||
| P/S LTM | x | 4.33 | 4.38 | |||||
| P/FCF LTM | x | -2.12 | -1.95 | |||||
| EV/EBITDA LTM | x | -1.52 | -1.34 | |||||
| EV/Sales LTM | x | 2.37 | 2.68 | |||||
| Earnings Yield LTM | % | -39.49% | -38.59% | |||||
| FCF Yield | % | -47.06% | -51.16% | |||||
| Quality | ||||||||
| ROE | % | 727.65% | 116.96% | |||||
| ROIC | % | -74.41% | -242.12% | |||||
| Operating margin | % | -181.09% | -312.53% | |||||
| Gross margin | % | 100.00% | 98.29% | |||||
| FCF/Sales | % | -203.65% | -327.72% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +9.88% | -4.76% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -2.88 | -32.43 | |||||
| Net Debt/EBITDA | x | 1.25 | 1.01 | |||||
| EBIT/Net interest | x | -18.93 | -28.52 | |||||
| Net debt/market cap | % | -63.44% | -38.79% | |||||
| Net debt/Equity | x | 11.69 | - | |||||
| Gross debt/equity | x | -3.01 | - | |||||
Company overview
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to pioneering novel antibody-drug conjugates (ADCs) for cancer patients with pressing unmet medical needs. Their flagship product candidate, XMT-1592, a Dolasynthen ADC engineered to target NaPi2b-expressing tumor cells, is presently undergoing Phase I clinical evaluation for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company's development pipeline also includes XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate, and XMT-2056, an Immunosynthen development candidate. Additionally, Mersana maintains strategic research and development collaborations with Merck KGaA and Asana BioSciences, LLC for the creation of ADC product candidates, leveraging its Fleximer technology. Incorporated in 2001, the company initially operated as Nanopharma Corp. before rebranding as Mersana Therapeutics, Inc. in November 2005, and is headquartered in Cambridge, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Mersana Therapeutics, Inc. (MRSN)
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to pioneering novel antibody-drug conjugates (ADCs) for cancer patients with pressing unmet medical needs. Their flagship product candidate, XMT-1592, a Dolasynthen ADC engineered to target NaPi2b-expressing tumor cells, is presently undergoing Phase I clinical evaluation for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company's development pipeline also includes XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate, and XMT-2056, an Immunosynthen development candidate. Additionally, Mersana maintains strategic research and development collaborations with Merck KGaA and Asana BioSciences, LLC for the creation of ADC product candidates, leveraging its Fleximer technology. Incorporated in 2001, the company initially operated as Nanopharma Corp. before rebranding as Mersana Therapeutics, Inc. in November 2005, and is headquartered in Cambridge, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free